Lifecore Biomedical Past Earnings Performance
Past criteria checks 0/6
Lifecore Biomedical's earnings have been declining at an average annual rate of -59.7%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been declining at an average rate of 32.9% per year.
Key information
-59.7%
Earnings growth rate
-59.7%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | -32.9% |
Return on equity | -183.1% |
Net Margin | -62.2% |
Last Earnings Update | 28 May 2023 |
Recent past performance updates
Recent updates
White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge
Apr 20Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?
Jun 30Landec Non-GAAP EPS of -$0.32, revenue of $43.35M
Oct 06Landec receives Nasdaq's notification on delayed annual report filing
Sep 09Laughing Water Capital - Landec Corp. : A High Quality CDMO
Jul 27Landec (NASDAQ:LNDC) Takes On Some Risk With Its Use Of Debt
Jun 24Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report
Apr 08Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet
Mar 21Here's What's Concerning About Landec's (NASDAQ:LNDC) Returns On Capital
Nov 30Optimistic About Landec's Strategic Initiatives And Sodium Hyaluronate Products
Nov 05Landec Still In Play As An Activist Investment
Aug 20Is Landec (NASDAQ:LNDC) Using Too Much Debt?
May 25Is Landec (NASDAQ:LNDC) Using Too Much Debt?
Feb 24The CEO, President & Director of Landec Corporation (NASDAQ:LNDC), Albert Bolles, Just Bought 38% More Shares
Jan 20Revenue & Expenses BreakdownBeta
How Lifecore Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
28 May 23 | 103 | -64 | 39 | 9 |
26 Feb 23 | 173 | -87 | 50 | 8 |
27 Nov 22 | 183 | -78 | 53 | 8 |
28 Aug 22 | 188 | -67 | 47 | 8 |
29 May 22 | 111 | -15 | 33 | 8 |
27 Feb 22 | 135 | -12 | 37 | 8 |
28 Nov 21 | 142 | -7 | 33 | 7 |
29 Aug 21 | 78 | -6 | 31 | 7 |
30 May 21 | 101 | -23 | 29 | 7 |
28 Feb 21 | 283 | -24 | 47 | 8 |
29 Nov 20 | 391 | -34 | 56 | 9 |
30 Aug 20 | 587 | -44 | 71 | 11 |
31 May 20 | 160 | -22 | 38 | 8 |
23 Feb 20 | 587 | -23 | 68 | 12 |
24 Nov 19 | 590 | -10 | 68 | 12 |
25 Aug 19 | 572 | -3 | 65 | 11 |
26 May 19 | 558 | 2 | 62 | 11 |
24 Feb 19 | 546 | 8 | 62 | 12 |
25 Nov 18 | 535 | 23 | 56 | 12 |
26 Aug 18 | 533 | 24 | 54 | 13 |
27 May 18 | 524 | 26 | 52 | 13 |
25 Feb 18 | 448 | 21 | 47 | 13 |
26 Nov 17 | 440 | 8 | 48 | 12 |
27 Aug 17 | 453 | 9 | 50 | 10 |
28 May 17 | 470 | 10 | 50 | 9 |
26 Feb 17 | 540 | 13 | 56 | 8 |
27 Nov 16 | 534 | -12 | 52 | 8 |
28 Aug 16 | 538 | -11 | 51 | 7 |
29 May 16 | 477 | -12 | 46 | 7 |
28 Feb 16 | 540 | -12 | 46 | 7 |
29 Nov 15 | 549 | 13 | 46 | 7 |
30 Aug 15 | 541 | 14 | 43 | 7 |
31 May 15 | 539 | 14 | 40 | 7 |
01 Mar 15 | 526 | 14 | 38 | 7 |
30 Nov 14 | 514 | 17 | 37 | 7 |
31 Aug 14 | 501 | 17 | 35 | 7 |
25 May 14 | 477 | 19 | 35 | 7 |
23 Feb 14 | 463 | 19 | 32 | 8 |
24 Nov 13 | 454 | 18 | 32 | 9 |
25 Aug 13 | 449 | 23 | 33 | 9 |
26 May 13 | 442 | 23 | 33 | 9 |
Quality Earnings: LFCR is currently unprofitable.
Growing Profit Margin: LFCR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LFCR is unprofitable, and losses have increased over the past 5 years at a rate of 59.7% per year.
Accelerating Growth: Unable to compare LFCR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LFCR is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: LFCR has a negative Return on Equity (-183.07%), as it is currently unprofitable.